Stockreport

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders [Yahoo! Finance...

NLS Pharmaceutics Ltd. - Common Shares  (NLSP) 
PDF clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disor [Read more]